Spine transforming into a tree, symbolizing resilience in ankylosing spondylitis

Decoding Ankylosing Spondylitis: Risks, Management, and Research Insights

Mira Elwood monogram
Mira Elwood in Health & Wellness November 2026 • 4 min read.

"Understand the complexities of ankylosing spondylitis, from increased surgical risks to the latest research impacting treatment strategies and patient outcomes."


Ankylosing spondylitis (AS) is a chronic inflammatory disorder primarily affecting the spine, leading to pain, stiffness, and potential long-term complications. Understanding the nuances of AS is crucial, especially for those diagnosed or at risk.

Recent studies have shed light on various aspects of AS, including surgical risks, gender-specific differences in disease progression, and the effectiveness of different treatment modalities. This information is vital for patients and healthcare providers to make informed decisions about managing the condition.

This article delves into these recent research findings, offering an accessible overview of the challenges and advancements in AS management. From understanding the heightened surgical risks associated with AS to exploring how gender influences the disease's trajectory, we aim to provide a comprehensive understanding of the latest insights.

AI Search Multiple angles on this topic

Surgical Risks

The supplied WebMD material identifies laminectomy, osteotomy, and spinal fusion as procedures with possible risks. It does not enumerate those risks in the excerpt provided. It also gives no statistics about how often these procedures are used or their impact.

A Developing History

A scoping review describes ankylosing spondylitis (AS) as a chronic, progressive inflammatory disease of the spine and sacroiliac (SI) joints, and notes that diagnostic criteria and treatments have continued to evolve. A 2024 historical review says it is possible that pharaohs such as Ramses II had an inflammatory spinal disease, presenting this as a likelihood rather than a confirmed diagnosis. The same review notes the established association between AS and HLA-B27, while observing that this association is less pronounced in some Arab countries.

Increased Surgical Risks in Ankylosing Spondylitis

Spine transforming into a tree, symbolizing resilience in ankylosing spondylitis

Individuals with ankylosing spondylitis face a significantly higher risk of needing spinal surgery, including cervical and lumbar procedures, compared to those without the condition. This increased risk underscores the importance of proactive management and careful consideration of surgical options.

The reasons for this elevated risk are multifactorial. AS can lead to spinal fusion and rigidity, making the spine more susceptible to fractures, even from minor trauma. Additionally, the inflammation and structural changes associated with AS can complicate surgical procedures and recovery.

  • Fracture Risk: Studies highlight a greater incidence of spinal fractures in AS patients, often requiring surgical intervention.
  • Kyphosis Correction: Surgical management may be necessary to correct severe kyphosis (spinal curvature) resulting from AS.
  • Post-operative Considerations: AS can affect bone healing and increase the risk of complications following spinal surgery.
AI Search Multiple angles on this topic

Uneven Response to TNF Inhibitors

Nature reports that tumor necrosis factor inhibitors (TNFi) have been used to manage active inflammation in AS. It also notes that not all patients respond to TNFi. The supplied material does not specify response rates, reasons for nonresponse, or which alternatives may help those patients.

Surgery Outcomes Under Study

A study published January 27, 2025, investigates outcomes of corrective spine surgery in people with AS using a retrospective cohort design. Its introduction describes AS as complex and says that comprehensive understanding of its pathogenesis remains elusive despite advances. The supplied excerpt does not report the study’s surgical outcomes, so it cannot establish from this material how often surgery succeeds or fails.

When Surgery Is Considered

A review of vertebral osteotomies notes that progressive thoracolumbar kyphosis can be debilitating for some people with AS, and that specific indications for surgical correction remain despite improving medical and conservative treatments. Medical News Today says most people manage AS with medication, exercise, and complementary treatments, though surgery may be considered for severe pain or reduced mobility. The supplied sources do not compare specific operations or establish that one approach is superior.

Given these risks, a thorough pre-surgical evaluation is essential for AS patients. This includes assessing bone density, spinal alignment, and overall health to optimize outcomes and minimize potential complications. Non-surgical management options, such as physical therapy and medication, should be exhausted whenever appropriate.

Moving Forward: Optimizing Care and Future Research

Managing ankylosing spondylitis requires a comprehensive approach that addresses both the symptoms and the underlying disease process. Recent research emphasizes the importance of personalized treatment strategies, considering individual risk factors, disease severity, and gender-specific differences.

AI Search Multiple angles on this topic

Balancing Surgical Need and Risk

A 2025 systematic review says surgery for traumatic spinal fractures in people with AS is often first-line treatment, while also carrying a high risk of perioperative complications. A separate report describes clinical results and surgical tactics for spinal osteotomy based on 428 patients with AS kyphosis treated from January 2003 through January 2015. The supplied material gives no outcome figures from either source, so it does not support a direct comparison of benefits and harms.

Precision and Combination Approaches

A report on global AS research trends describes treatment research evolving from tumor necrosis factor inhibitors to include interleukin-17 inhibitors. It anticipates more research into precision medicine and combination therapies; this is a projection, not a confirmed clinical outcome. A separate market-report snippet says it covers real-world prescription patterns, emerging therapies, individual drug market shares, and historical and forecasted markets across the 7MM.

Convenience in Treatment

A case series reports on CT-P13 SC, described as the first subcutaneous form of infliximab used for AS. Its authors report that it provided safe and effective treatment in their case series. They also describe greater convenience than intravenous treatment, including during the pandemic and beyond.

Continued research is crucial to further refine our understanding of AS and develop more effective treatments. Areas of focus include identifying biomarkers for early diagnosis, exploring novel therapeutic targets, and improving surgical techniques to minimize risks and optimize outcomes.

By staying informed about the latest research and working closely with healthcare providers, individuals with AS can take proactive steps to manage their condition and improve their quality of life. The insights from these studies empower patients and clinicians alike to make more informed decisions and strive for better long-term outcomes.

TNFi adverse events compared with placebo

  • OR 1.55, 95% CI 1.31–1.82Across trials involving 3,221 participants, TNFi groups had higher odds of overall adverse events than placebo groups (OR 1.55, 95% CI 1.31–1.82).[1]
  • 35At week 6, the estimated ASAS20 response was 59% with secukinumab and 24% with placebo, a 35-percentage-point difference.[2]

What treatment comparisons show-and do not show

The placebo comparison indicates that overall adverse events were more likely in the TNFi groups, but it does not say which events accounted for that difference or how they affected individual patients.[1]

The secukinumab result places its response estimate alongside a placebo baseline at a specified time point; it does not establish how responses compare with other treatments or persist beyond that point.[2]

Different studies address different AS questions

A review of spinal osteotomy reports a complication rate of 6.5% for one-level procedures and 23.6% for two-level procedures. The source also frames the work as an evaluation of the procedures’ efficacy and feasibility, rather than a comparison that by itself settles which approach is preferable.[3]

The diagnostic sources describe MRI as enabling detection before structural damage becomes visible on X-rays, and say assessment can draw on clinical characteristics, HLA-B27 status, MRI, and sometimes other biomarkers. The evidence also notes that AS can occur alongside peripheral or extra-articular disease, while cardiovascular risk in axial SpA is discussed in relation to disease burden and other factors.[4] [5] [6] [7]

What the comparisons leave unresolved

  • Do the complication differences between one-level and two-level osteotomy reflect the procedures themselves or differences in the patients and cases selected for each? The reported comparison does not resolve that question on its own.[3]

Sources

  1. Adverse events of tumor necrosis factor alpha inhibitors for the treatment of ankylosing spondylitis: A meta-analysis of randomized, placebo-controlled trials (pmc.ncbi.nlm.nih.gov)
  2. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. (pubmed.ncbi.nlm.nih.gov)
  3. Clinical results and surgery tactics of spinal osteotomy for ankylosing spondylitis kyphosis: experience of 428 patients (pmc.ncbi.nlm.nih.gov)
  4. Classification vs diagnostic criteria: the challenge of diagnosing axial spondyloarthritis (pmc.ncbi.nlm.nih.gov)
  5. A guideline on biomarkers in the diagnosis and evaluation in axial spondyloarthritis (pmc.ncbi.nlm.nih.gov)
  6. Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis (pmc.ncbi.nlm.nih.gov)
  7. Cardiovascular risk in axial spondyloarthritis—a systematic review (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What is Ankylosing spondylitis (AS)?

Ankylosing spondylitis (AS) is a chronic inflammatory disorder that mainly affects the spine. It's characterized by pain, stiffness, and potential long-term complications. This condition can lead to significant challenges, including increased surgical risks, making it crucial for those diagnosed or at risk to understand its nuances for effective management.

2

Why is there an increased risk of needing surgery for those with Ankylosing spondylitis (AS)?

Individuals with Ankylosing spondylitis (AS) face a higher likelihood of requiring spinal surgery. This includes procedures on both the cervical and lumbar spine. The increased surgical risk stems from AS-related spinal fusion and rigidity, which heighten the susceptibility to fractures even from minor incidents. The inflammation and structural changes associated with AS further complicate the surgical process and recovery phase.

3

What are the specific surgical risks associated with Ankylosing spondylitis (AS)?

Spinal fractures are more prevalent in individuals with Ankylosing spondylitis (AS), often necessitating surgical intervention. AS can lead to severe kyphosis, a spinal curvature, that may also require surgical correction. Post-operative considerations are critical because AS can affect bone healing and increase the possibility of complications following spinal surgery.

4

How should Ankylosing spondylitis (AS) be managed?

Management of Ankylosing spondylitis (AS) should be comprehensive, addressing both symptoms and the underlying disease. Recent research advocates for personalized treatment strategies, factoring in individual risk factors, the severity of the disease, and gender-specific differences. This tailored approach is vital for optimizing patient outcomes and improving quality of life.

5

Why are gender-specific differences important in the context of Ankylosing spondylitis (AS)?

Gender-specific differences in Ankylosing spondylitis (AS) are important to understand as they can influence the disease's trajectory. Research provides insights into how AS affects men and women differently, which is key to personalized treatment. Considering these differences is crucial for tailoring management strategies to optimize outcomes.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.